Filing Details

Accession Number:
0001140361-24-047702
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-22 21:05:18
Reporting Period:
2024-11-22
Accepted Time:
2024-11-22 21:05:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1368514 Adma Biologics Inc. ADMA Biological Products, (No Disgnostic Substances) (2836) 562590442
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
2030561 L. Brad Tade C/O Adma Biologics, Inc.
5800 Park Of Commerce Blvd. Nw
Boca Raton FL 33487
Cfo And Treasurer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-11-22 15,000 $21.15 199,433 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. These shares represent restricted stock units ("RSUs") that were granted on June 26, 2023 and vested on June 26, 2024.
  2. Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;
  3. (continued from footnote 2) (ii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;
  4. (continued from footnote 3) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs.